Home /
news Podcasts /
The Journal. /
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

EPISODE · May 21, 2025 · 19 MIN

Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

from The Journal. · host The Wall Street Journal & Spotify Studios

Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts. Further Listening: Trillion Dollar Shot Why WeightWatchers Wants in on Drugs Like Ozempic Sign up for WSJ’s free What’s News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode metadata supplied by the publisher feed · Published May 21, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

0:00 19:12

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Journal.?

This episode is 19 minutes long.

When was this The Journal. episode published?

This episode was published on May 21, 2025.

Can I download this The Journal. episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!